Fig. 8From: Midazolam exhibits antitumour and enhances the efficiency of Anti-PD-1 immunotherapy in hepatocellular carcinomaSchematic diagram of the changes in the tumour immune microenvironment of subcutaneous tumour-bearing mouse models after MDZ treatment. MDZ inhibited subcutaneous HCC tumour growth and enhanced anti-PD-1 monoclonal antibody immunity in HCCBack to article page